SCHEMBL6301115

SCHEMBL6301115

CCc1cc2cc(C(=O)OC)ccc2o1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.49
POLB P06746 1/20 0.49
THRB P10828 1/20 0.49
SLC22A12 Q96S37 3/20 0.46
HDAC6 Q9UBN7 2/20 0.44
CREBBP Q92793 1/20 0.44
F2 P00734 1/20 0.44
F10 P00742 1/20 0.44
CA12 O43570 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
KDM4E B2RXH2 1/20 0.44
CA3 P07451 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA5B Q9Y2D0 1/20 0.44
MAPT P10636 4/20 0.44
CA1 P00915 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5027947 0.89 F2 (0.56) TP53POLBTHRBHDAC6CREBBP
SCHEMBL6298871 0.88 F2 (0.49) TP53POLBTHRBHDAC6CREBBP
SCHEMBL24570865 0.88 HDAC6 (0.52) TP53POLBTHRBHDAC6CREBBP
SCHEMBL30514526 0.88 HDAC6 (0.52) TP53POLBTHRBHDAC6CREBBP
SCHEMBL5032872 0.87 F2 (0.50) TP53POLBTHRBHDAC6CREBBP
SCHEMBL5034766 0.87 F2 (0.50) TP53POLBTHRBHDAC6CREBBP
SCHEMBL17078875 0.87 TP53 (0.48) TP53POLBTHRBHDAC6CREBBP
SCHEMBL5673192 0.86 F2 (0.47) TP53POLBTHRBHDAC6CREBBP
SCHEMBL6489985 0.85 TP53 (0.47) TP53POLBTHRBHDAC6CREBBP
SCHEMBL5032864 0.85 F2 (0.49) TP53POLBTHRBHDAC6CREBBP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6911469-B2 Sulfonamide compounds and pharmaceutical use thereof FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-06-28 US disclosed
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-09-16 US disclosed
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity FUJISAWA PHARMACEUTICAL CO. LTD. (JP) 2002-07-25 US disclosed
US-6348474-B1 COMPOUNDS AS ANTIDIABETIC AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2002-02-19 US disclosed
EP-0995742-A1 SULFONAMIDE COMPOUNDS AND MEDICINAL USE THEREOF FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-26 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099212-A1 For therapy of disease treatable based on a blood sugar level-depressing activity or a disease treatable based on a cGMP-PDE inhibiting activity, smooth muscle relaxing activity, bronchodilating activity, vasodilating activity PDE2A, PDE3A, PDE12 TP53 4884/4885POLB 2385/4885THRB 1313/4885
US-20040180947-A1 hypoglycemic activity or phoshodiesterase-V inhibitory activity; prophylaxis and treatment of impaired glucose tolerance disorder, diabetes (e.g., type II diabetes), diabetic complications PDE2A, PDE3A, PYGM TP53 4849/4885POLB 1050/4885THRB 1284/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.